TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24277644

Group type: EXPERIMENTAL
Intervention: Activated charcoal administered at 2 hours post-dose
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Activated charcoal administered at 6 hours post-dose
Number of subjects: 18

Group type: COMPARATOR
Intervention: Apixaban alone
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Activated charcoal administered at 2 or 6 hours post-dose
Number of subjects: 18
Study: 22422538

Group type: EXPERIMENTAL
Intervention: Frequent hemodialysis (six times per week)
Number of subjects: 332

Group type: COMPARATOR
Intervention: Conventional hemodialysis (three times per week)
Number of subjects: 332
Study: 18815591

Group type: EXPERIMENTAL
Intervention: Ritonavir 20 mg
Number of subjects: 0
Study: 18575010

Group type: EXPERIMENTAL
Intervention: Mitomycin C (0.5 mg/ml) applied intra- and postoperatively for 5 minutes
Number of subjects: 30

Group type: COMPARATOR
Intervention: Saline (control) applied in the contralateral side
Number of subjects: 30
Study: 15707804

Group type: EXPERIMENTAL
Intervention: Ultrasound measurement of abdominal aortic diameter by emergency physicians
Number of subjects: 104
Study: 12085859

Group type: EXPERIMENTAL
Intervention: Atraumatic restorative treatment (ART)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Conventional cavity preparation
Number of subjects: 68

Group type: COMPARATOR
Intervention: High-copper-content GK Amalgam Alloy (control)
Number of subjects: 68
Study: 10102460

Group type: EXPERIMENTAL
Intervention: Melagatran (low dose)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Melagatran (medium dose)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Melagatran (high dose)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 48
Study: 8697064

Group type: EXPERIMENTAL
Intervention: Testosterone (T)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dihydrotestosterone (DHT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 0
Study: 2348224

Group type: EXPERIMENTAL
Intervention: liposome‐encapsulated doxorubicin (LED) at 30 mg/m2
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: liposome‐encapsulated doxorubicin (LED) at 45 mg/m2
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: liposome‐encapsulated doxorubicin (LED) at 60 mg/m2
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: liposome‐encapsulated doxorubicin (LED) at 90 mg/m2
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: liposome‐encapsulated doxorubicin (LED)
Number of subjects: 14
Study: 375768

Group type: EXPERIMENTAL
Intervention: Dantrolene (100-150 mg)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Suxamethonium
Number of subjects: 48
Study: 31250168

Group type: EXPERIMENTAL
Intervention: Intrarectal instillation of 2% lidocaine gel (group A)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Periprostatic nerve block (PPNB) with 2% mepivacaine (group B)
Number of subjects: 252
Study: 28510574

Group type: EXPERIMENTAL
Intervention: High initial dosage (10 vials) of Indian polyvalent antivenom
Number of subjects: 154

Group type: COMPARATOR
Intervention: Low initial dosage (2 vials) of Indian polyvalent antivenom
Number of subjects: 154
Study: 25522681

Group type: EXPERIMENTAL
Intervention: General anaesthesia
Number of subjects: 120

Group type: COMPARATOR
Intervention: Spinal anaesthesia
Number of subjects: 120
Study: 23442273

Group type: EXPERIMENTAL
Intervention: Daily Nonlinear Periodized (DNLP) training
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Nonperiodized (NP) training
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 38
Study: 21168464

Group type: EXPERIMENTAL
Intervention: RIS oral solution (mean dose, 3.7 mg)
Number of subjects: 81

Group type: COMPARATOR
Intervention: RIS standard tablets (mean dose, 3.7 mg)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: RIS oral solution
Number of subjects: 81

Group type: COMPARATOR
Intervention: RIS standard tablets
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Both RIS oral solution and RIS standard tablets
Number of subjects: 81
Study: 19506071

Group type: EXPERIMENTAL
Intervention: Mirror visual feedback
Number of subjects: 0
Study: 17888158

Group type: EXPERIMENTAL
Intervention: Primary School Free Breakfast Initiative (intervention group, 55 schools)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Control condition (control group, 56 schools)
Number of subjects: 111
Study: 14750044

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Depressive mood
Number of subjects: 41
Study: 12645162

Group type: EXPERIMENTAL
Intervention: Theta feedback, a non-pharmacologic technique
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multi-model approach combining pharmacologic and non-pharmacologic interventions
Number of subjects: 0
Study: 9802004

Group type: EXPERIMENTAL
Intervention: Integrative Behavioral Couple Therapy (IBCT)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Traditional Behavioral Couple Therapy (TBCT)
Number of subjects: 2
Study: 7618022

Group type: EXPERIMENTAL
Intervention: Zolpidem 7.5 mg
Number of subjects: 462

Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg
Number of subjects: 462

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 462

Group type: EXPERIMENTAL
Intervention: Zolpidem 7.5 mg and 10 mg
Number of subjects: 462
Study: 2507698

Group type: EXPERIMENTAL
Intervention: Vitamin B1, B6, and B12 (Neurobion or Neurobion forte)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17

Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 17
Study: 666931

Group type: EXPERIMENTAL
Intervention: Extradural anaesthesia (mepivacaine, lignocaine, or bupivacaine)
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: General anaesthesia
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Bottle-fed subgroup
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Breast-fed subgroup
Number of subjects: 241

Group type: COMPARATOR
Intervention: Control group (delivered without anaesthesia)
Number of subjects: 241
Study: 31883339

Group type: EXPERIMENTAL
Intervention: Low baseline BNP (<50 pg/mL)
Number of subjects: 1782

Group type: EXPERIMENTAL
Intervention: Moderately elevated baseline BNP (≥100 and <400 pg/mL)
Number of subjects: 1782

Group type: EXPERIMENTAL
Intervention: Markedly elevated baseline BNP (≥400 pg/mL)
Number of subjects: 1782

Group type: COMPARATOR
Intervention: Normal baseline BNP (≥50 and <100 pg/mL)
Number of subjects: 1782
Study: 30301734

Group type: EXPERIMENTAL
Intervention: 17β-estradiol transdermal patch continuously with cyclic oral micronised progesterone (PATCH)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Combined ethinyl estradiol and desogestrel pill (PILL)
Number of subjects: 121

Group type: COMPARATOR
Intervention: No oestrogen/progesterone (NONE)
Number of subjects: 121
Study: 29130797

Group type: EXPERIMENTAL
Intervention: 300 UA/day
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: 600 UA/day
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: 1000 UA/day
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: 2000 UA/day
Number of subjects: 158
Study: 25510770

Group type: EXPERIMENTAL
Intervention: Speech noise (45 dB)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Background noise (35 dB)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Traffic noise (45 dB)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Mixed noise (traffic and speech, 45 dB)
Number of subjects: 40
Study: 23916525

Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 42

Group type: COMPARATOR
Intervention: Valproate
Number of subjects: 42
Study: 21623743

Group type: EXPERIMENTAL
Intervention: CTG+ST (Cardiotocography plus ST analysis of fetal electrocardiogram)
Number of subjects: 5049

Group type: COMPARATOR
Intervention: CTG-only (Cardiotocography only)
Number of subjects: 5049
Study: 19537954

Group type: EXPERIMENTAL
Intervention: Smoking cessation intervention (details not provided)
Number of subjects: 184
Study: 16529048

Group type: EXPERIMENTAL
Intervention: LHRH agonist
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exemestane
Number of subjects: 0
Study: 15270209

Group type: EXPERIMENTAL
Intervention: Ovarian stimulation with smooth protocol and insemination of 5 million progressive motile sperm over two consecutive days
Number of subjects: 710

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 710
Study: 10978851

Group type: EXPERIMENTAL
Intervention: Oral dietary supplements (ODS) pre- and postoperatively
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Oral dietary supplements (ODS) preoperatively only
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Oral dietary supplements (ODS) postoperatively only
Number of subjects: 100

Group type: COMPARATOR
Intervention: No oral dietary supplements (Control group)
Number of subjects: 100
Study: 8818086

Group type: EXPERIMENTAL
Intervention: Group A received 2 x 10(6) units of aprotinin 15 min before ECC and 0.5 x 10(6) unit immediately after ECC.
Number of subjects: 14

Group type: COMPARATOR
Intervention: Group B received 0.5 x 10(6) unit of aprotinin 15 min before ECC and 2 x 10(6) units immediately after ECC.
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Both groups received aprotinin at different dosages and timings.
Number of subjects: 14
Study: 1681563

Group type: EXPERIMENTAL
Intervention: Abecarnil 3-9 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Abecarnil 15-30 mg/day and 7.5-15 mg/day
Number of subjects: 0
Study: 6130080

Group type: EXPERIMENTAL
Intervention: buspirone, 20 mg/day
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: diazepam, 20 mg/day
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: clorazepate, 23 mg/day
Number of subjects: 1000

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1000
Study: 30461447

Group type: EXPERIMENTAL
Intervention: Axillary brachial plexus block
Number of subjects: 82

Group type: COMPARATOR
Intervention: Infraclavicular brachial plexus block
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 82
Study: 27605024

Group type: EXPERIMENTAL
Intervention: Finalized data abstraction tool
Number of subjects: 1440

Group type: COMPARATOR
Intervention: Preliminary data abstraction tool
Number of subjects: 1440
Study: 25785969

Group type: EXPERIMENTAL
Intervention: 13-valent polysaccharide conjugate vaccine (PCV13)
Number of subjects: 84496

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84496
Study: 23878205

Group type: EXPERIMENTAL
Intervention: Knee sleeve alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stochastic resonance electrical stimulation with knee sleeve
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control1 (no electrical stimulation/sleeve)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control2
Number of subjects: 0
Study: 22178632

Group type: EXPERIMENTAL
Intervention: Strength training prior to endurance training (SE)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Strength training after endurance training (ES)
Number of subjects: 26
Study: 20730057

Group type: EXPERIMENTAL
Intervention: Micronutrient fortified milk (MN milk)
Number of subjects: 633

Group type: COMPARATOR
Intervention: Control milk (Co milk)
Number of subjects: 633
Study: 18947396

Group type: EXPERIMENTAL
Intervention: Lipoplus 20% (50% MCT, 40% LCT, 10% omega‐3) administered at a dose of 0.12 g/kg/h for 12 hours
Number of subjects: 16

Group type: COMPARATOR
Intervention: Intralipid Fresenius Kabi (100% LCT) administered at a dose of 0.12 g/kg/h for 12 hours
Number of subjects: 16
Study: 15833501

Group type: EXPERIMENTAL
Intervention: Pentosan polysulfate sodium (PPS) 300 mg
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Pentosan polysulfate sodium (PPS) 600 mg
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Pentosan polysulfate sodium (PPS) 900 mg
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Pentosan polysulfate sodium (PPS) (all dosages)
Number of subjects: 380
Study: 11791087

Group type: EXPERIMENTAL
Intervention: Oral conjugated estrogen 0.625 mg and medroxyprogesterone acetate 2.5 mg per day
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Reduced dose of oral conjugated estrogen
Number of subjects: 18

Group type: COMPARATOR
Intervention: Calcium supplement (control group)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (full and reduced dose)
Number of subjects: 18
Study: 10527987

Group type: EXPERIMENTAL
Intervention: Shortened exposure of oocytes to spermatozoa
Number of subjects: 158

Group type: COMPARATOR
Intervention: Conventional treatment time (standard IVF procedure)
Number of subjects: 158
Study: 7724171

Group type: EXPERIMENTAL
Intervention: Photorefractive keratectomy (PRK)
Number of subjects: 106
Study: 2756927

Group type: EXPERIMENTAL
Intervention: Hydrostatic weighing without head submersion (HWNS)
Number of subjects: 80
Study: 1066813

Group type: EXPERIMENTAL
Intervention: Chlorhexidine gel (0.2% chlorhexidine gluconate) used 3 times a day for 6 weeks
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Chlorhexidine solution (various concentrations: 0.05%, 0.1%, 0.15%, 0.2%) rinsed twice a day for 7 days
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 16
Study: 31313755

Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation intervention over 12 months
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Hamilton anxiety scale
Number of subjects: 104

Group type: COMPARATOR
Intervention: Beck's depression inventory
Number of subjects: 104
Study: 29465209

Group type: EXPERIMENTAL
Intervention: Vizomitin (eye drops)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Natural tear
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control (no specific pharmacological prevention)
Number of subjects: 70
Study: 25959261

Group type: EXPERIMENTAL
Intervention: Atrial-based pacing at increased heart rate
Number of subjects: 239
Study: 24041309

Group type: EXPERIMENTAL
Intervention: Anticipated regret questionnaire
Number of subjects: 60000

Group type: COMPARATOR
Intervention: Control questionnaire
Number of subjects: 60000

Group type: COMPARATOR
Intervention: No questionnaire
Number of subjects: 60000
Study: 21443986

Group type: EXPERIMENTAL
Intervention: Q-500 (500 mg quercetin, 125 mg vitamin C, and 5 mg niacin)
Number of subjects: 1002

Group type: EXPERIMENTAL
Intervention: Q-1,000 (1,000 mg quercetin, 250 mg vitamin C, and 10 mg niacin)
Number of subjects: 1002

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1002
Study: 19577483

Group type: EXPERIMENTAL
Intervention: Soy group (28 g/day textured soy flour for 8 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (usual diet without soy)
Number of subjects: 40
Study: 21842299

Group type: EXPERIMENTAL
Intervention: Polyhexamethylene biguanide-impregnated gauze
Number of subjects: 38

Group type: COMPARATOR
Intervention: Plain gauze (control)
Number of subjects: 38
Study: 16288151

Group type: EXPERIMENTAL
Intervention: Self‐efficacy‐based Basic Life Support (SEBLS) program
Number of subjects: 38
Study: 12860500

Group type: EXPERIMENTAL
Intervention: Galantamine 16 mg/d
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Galantamine 24 mg/d
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Galantamine (limited to responders)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No pharmacologic treatment (Control)
Number of subjects: 0
Study: 9583728

Group type: EXPERIMENTAL
Intervention: Cisplatin and etoposide with recombinant interferon
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Cisplatin and etoposide with leukocyte interferon
Number of subjects: 68

Group type: COMPARATOR
Intervention: Cisplatin and etoposide without interferon
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: High pre-treatment S-VEGF (>527 pg/ml)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Low pre-treatment S-VEGF (n = 17, 25% of all patients)
Number of subjects: 68
Study: 7661070

Group type: EXPERIMENTAL
Intervention: Hydrochlorthiazide
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 2573208

Group type: EXPERIMENTAL
Intervention: Famotidine 20 mg q12h
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cimetidine 300 mg q6h or q12h
Number of subjects: 0
Study: 1275217

Group type: EXPERIMENTAL
Intervention: Preoperative haemodilution with Dextran 60
Number of subjects: 0

Group type: COMPARATOR
Intervention: Preoperative haemodilution with Dextran 40
Number of subjects: 0
Study: 12297808

Group type: EXPERIMENTAL
Intervention: Gatifloxacin 400 mg once daily for 10 days
Number of subjects: 11000

Group type: EXPERIMENTAL
Intervention: Gatifloxacin
Number of subjects: 11000
Study: 31045789

Group type: EXPERIMENTAL
Intervention: Serratus plane block (SPB) with 20 ml of 0.375% ropivacaine
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Serratus plane block (SPB)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional general anesthesia
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study: 29463119

Group type: EXPERIMENTAL
Intervention: Communities That Care (CTC) prevention system
Number of subjects: 4407
Study: 26573217

Group type: EXPERIMENTAL
Intervention: Eteplirsen (30/50mg/kg)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Eteplirsen
Number of subjects: 25

Group type: COMPARATOR
Intervention: Historical Control (HC)
Number of subjects: 25
Study: 24502880

Group type: EXPERIMENTAL
Intervention: GDF-15 >1800 ng/L
Number of subjects: 1151

Group type: COMPARATOR
Intervention: GDF-15 <1200 ng/L
Number of subjects: 1151
Study: 22410599

Group type: EXPERIMENTAL
Intervention: Short-term life review (60 minutes, twice a week)
Number of subjects: 32
Study: 20453155

Group type: EXPERIMENTAL
Intervention: Action observation (watching video clips showing specific movements and strategies to circumvent FOG episodes)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Landscape (watching video clips of static pictures showing different landscapes)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups underwent identical physical therapy training (3 sessions a week for 4 weeks)
Number of subjects: 20
Study: 18789901

Group type: EXPERIMENTAL
Intervention: Rotigaptide (0.25-25 nmol/min)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Acetylcholine (5-20 microg/min)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Bradykinin (30-300 pmol/min)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (2-8 microg/min)
Number of subjects: 27
Study: 15744332

Group type: EXPERIMENTAL
Intervention: Glu298Asp polymorphism carriers (298Asp allele)
Number of subjects: 294

Group type: COMPARATOR
Intervention: Glu/Glu homozygotes
Number of subjects: 294
Study: 11926939

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 9461369

Group type: EXPERIMENTAL
Intervention: salbutamol (0.25 ml Ventolin 0.5%)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: ipratropium bromide (0.25 ml Atrovent 0.025%)
Number of subjects: 52

Group type: COMPARATOR
Intervention: none (control group: patients who did not develop BPD)
Number of subjects: 52

Group type: COMPARATOR
Intervention: none (routine administration of bronchodilators)
Number of subjects: 52
Study: 9097801

Group type: EXPERIMENTAL
Intervention: Dysplastic nevus syndrome
Number of subjects: 162

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 162
Study: 2651951

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 7

Group type: COMPARATOR
Intervention: Slow channel calcium entry blocker (Ca antagonist)
Number of subjects: 7
Study: 1268475

Group type: EXPERIMENTAL
Intervention: Proximal gastric vagotomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Truncal vagotomy and antrectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multiple abnormalities present
Number of subjects: 0
Study: 31596110

Group type: EXPERIMENTAL
Intervention: MIP60 (trained group at 60% of the maximal inspiratory pressure)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: CIP (trained group at critical inspiratory pressure)
Number of subjects: 30

Group type: COMPARATOR
Intervention: SHAM (sham-trained group)
Number of subjects: 30
Study: 28585868

Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behavioral therapy (ICBT)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 90
Study: 25325342

Group type: EXPERIMENTAL
Intervention: Gum chewing (started at post-operative 3rd hour, chewed every 4 hours for 30 minutes)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Control group (no gum chewing)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Gum chewing
Number of subjects: 137
Study: 23127158

Group type: EXPERIMENTAL
Intervention: Localized radiofrequency heat (RFH) therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20952228

Group type: EXPERIMENTAL
Intervention: IVRO plus coronoidotomy
Number of subjects: 56

Group type: COMPARATOR
Intervention: Simple IVRO
Number of subjects: 56
Study: 19523421

Group type: EXPERIMENTAL
Intervention: DHAD‐PBCA‐NPs
Number of subjects: 108

Group type: COMPARATOR
Intervention: DHAD injection
Number of subjects: 108
Study: 17000418

Group type: EXPERIMENTAL
Intervention: Early persistent middle ear effusion (MEE)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Control group (children without early MEE)
Number of subjects: 226
Study: 12749489

Group type: EXPERIMENTAL
Intervention: Insecticide-treated bed nets (ITNs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no ITNs)
Number of subjects: 0
Study: 11015815

Group type: EXPERIMENTAL
Intervention: Olanzapine 5 mg/d
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Olanzapine 10 mg/d
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Olanzapine 15 mg/d
Number of subjects: 206

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Olanzapine (all doses)
Number of subjects: 206